Project Grant K99CA300498
Award Date 9/2/25
Completion Date 8/31/27
Dollars Obligated $138K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The federal Project Grant award in the amount of $159,304 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The award was granted to the Dana-Farber Cancer Institute, Inc. (DFCI) to support research on signaling pathways in tumoricidal macrophages in pancreatic cancer. The key objectives of the project include defining the role of deubiquitinases in regulating macrophage surface receptors that govern the recognition and phagocytosis...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- The Project Grant award of $523,480.00 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The funding supports research aimed at understanding and overcoming therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC), the third most common cause of cancer-related death in the U.S. Specifically, the project will investigate how disrupting iron metabolism and autophagy pathways...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $303,475 to Pulse Biosciences, Inc. to develop a new two-component treatment for pancreatic ductal adenocarcinoma (PDAC). The primary objectives are to: 1) Deliver nanosecond electric pulses to pancreatic tumors using endoscopic ultrasound-guided bipolar catheters to trigger immunogenic cell death, and 2) Inject an immune system stimulant into the tumor to generate an in situ...
- This Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), funds the development and validation of a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The $400,835 award to Cambium Oncology LLC aims to engineer CAR-T cells that can secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment in PDAC. The 1-year project involves developing and validating...
- The National Cancer Institute (NCI) awarded a $170,641 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The purpose of this 2-year award, which runs from August 1, 2025 to July 31, 2027, is to advance the understanding of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers. The research aims to identify immunologically distinct subsets of mismatch-repair proficient...